Trials / Completed
CompletedNCT00660920
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Ariad Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ponatinib | Comparison of different dosages of drug given orally once per day. |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2008-04-17
- Last updated
- 2018-05-16
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00660920. Inclusion in this directory is not an endorsement.